Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index
Abeona Therapeutics (Nasdaq: ABEO) has been added to both the Russell 2000® Index and the Russell 3000® Index as part of the indexes' annual reconstitution, effective June 30, 2025. This inclusion follows the recent FDA approval of the company's product ZEVASKYN™.
The Russell indexes, which benchmark approximately $10.6 trillion in assets, are widely utilized by investment managers and institutional investors for index funds and active investment strategies. Membership in these indexes is reviewed annually and maintains for one year.
Abeona Therapeutics (Nasdaq: ABEO) è stata inclusa sia nell'Indice Russell 2000® che nell'Indice Russell 3000® nell'ambito della ricostituzione annuale degli indici, con effetto dal 30 giugno 2025. Questa inclusione segue la recente approvazione da parte della FDA del prodotto ZEVASKYN™ dell'azienda.
Gli indici Russell, che rappresentano un benchmark per circa 10,6 trilioni di dollari in asset, sono ampiamente utilizzati dai gestori di investimenti e dagli investitori istituzionali per fondi indicizzati e strategie di investimento attive. L'appartenenza a questi indici viene rivista annualmente e dura un anno.
Abeona Therapeutics (Nasdaq: ABEO) ha sido añadida tanto al Índice Russell 2000® como al Índice Russell 3000® como parte de la reconstitución anual de los índices, con vigencia a partir del 30 de junio de 2025. Esta inclusión sigue a la reciente aprobación por parte de la FDA del producto ZEVASKYN™ de la compañía.
Los índices Russell, que sirven como referencia para aproximadamente 10,6 billones de dólares en activos, son ampliamente utilizados por gestores de inversiones e inversores institucionales para fondos indexados y estrategias de inversión activas. La membresía en estos índices se revisa anualmente y se mantiene por un año.
Abeona Therapeutics (나스닥: ABEO)가 지수 연례 재구성의 일환으로 러셀 2000® 지수와 러셀 3000® 지수에 모두 포함되었으며, 이는 2025년 6월 30일부터 발효됩니다. 이번 포함은 회사 제품 ZEVASKYN™의 최근 FDA 승인에 따른 것입니다.
러셀 지수는 약 10.6조 달러 규모의 자산을 벤치마크로 삼으며, 투자 관리자와 기관 투자자들이 인덱스 펀드 및 적극적 투자 전략에 널리 활용합니다. 이 지수의 구성원 자격은 매년 검토되며 1년간 유지됩니다.
Abeona Therapeutics (Nasdaq : ABEO) a été ajoutée à la fois au Russell 2000® Index et au Russell 3000® Index dans le cadre de la reconstitution annuelle des indices, effective à partir du 30 juin 2025. Cette inclusion fait suite à l'approbation récente par la FDA du produit ZEVASKYN™ de la société.
Les indices Russell, qui servent de référence pour environ 10,6 billions de dollars d'actifs, sont largement utilisés par les gestionnaires d'investissements et les investisseurs institutionnels pour les fonds indiciels et les stratégies d'investissement actives. L'appartenance à ces indices est révisée chaque année et est maintenue pendant un an.
Abeona Therapeutics (Nasdaq: ABEO) wurde im Rahmen der jährlichen Neukonstituierung der Indizes sowohl in den Russell 2000® Index als auch in den Russell 3000® Index aufgenommen, wirksam ab dem 30. Juni 2025. Diese Aufnahme folgt auf die kürzliche FDA-Zulassung des Produkts ZEVASKYN™ des Unternehmens.
Die Russell-Indizes, die als Benchmark für etwa 10,6 Billionen US-Dollar an Vermögenswerten dienen, werden von Investmentmanagern und institutionellen Anlegern häufig für Indexfonds und aktive Anlagestrategien genutzt. Die Mitgliedschaft in diesen Indizes wird jährlich überprüft und gilt für ein Jahr.
- None.
- None.
CLEVELAND, June 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it was added as a member of the U.S. small-cap Russell 2000® Index and the broad-market Russell 3000® Index as part of the reconstitution of the Russell stock indexes, effective at the open of the U.S. equity markets today.
“Abeona's addition to the Russell 2000 and 3000 indexes, on the heels of ZEVASKYN™'s FDA approval, represents a pivotal moment for the company,” said Joe Vazzano, Chief Financial Officer of Abeona. “This inclusion amplifies our positive momentum as we progress with ZEVASKYN's commercial launch and provides an opportunity to engage with a broader audience of investors.”
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about
Membership in the Russell 3000® Index means automatic inclusion in either the large-cap Russell 1000® Index or small-cap Russell 2000® Index, as well as the appropriate growth and value style indexes. The Russell 3000® Index encompasses the 3,000 largest U.S.-traded stocks by objective, market-capitalization rankings, and style attributes. Membership in these indexes is updated annually and remains in place for one year. For more information on the Russell 2000® and Russell 3000® Indexes and the Russell U.S. Indexes Reconstitution, visit the “Russell Reconstitution” section on the FTSE Russell website.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN™ (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.
ZEVASKYNTM, Abeona AssistTM, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, our ability to commercialize ZEVASKYN, the therapeutic potential of ZEVASKYN, whether the unmet need and market opportunity for ZEVASKYN are consistent with the Company’s expectations, continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with and inspections from the FDA or other regulatory agencies, including those relating to preclinical programs; the ability to achieve or obtain necessary regulatory approvals; the impact of any changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
Investor and Media Contact: Greg Gin VP, Investor Relations and Corporate Communications Abeona Therapeutics ir@abeonatherapeutics.com
FAQ
What indexes was Abeona Therapeutics (ABEO) added to in June 2025?
How long will Abeona Therapeutics (ABEO) remain in the Russell indexes?
What is the significance of ABEO joining the Russell indexes?
How much in assets are benchmarked against Russell U.S. indexes?
What recent product approval did Abeona Therapeutics receive?
